Skip to content
Learning from “Elite” Responders to Develop Better Immunotherapies episode artwork

Oct 27, 2022 28 min

Learning from “Elite” Responders to Develop Better Immunotherapies

from The Bio Report Hosted by Levine Media Group

A subset of patients treated with checkpoint inhibitors respond particularly well to these immunotherapies. These so-called “elite responders” produce antibodies that modulate immune cells in the tumor microenvironment. OncoResponse is working to discover the antibodies these elite responders produce to develop a pipeline of cancer therapies. We spoke to Bob Lechleider, chief medical officer of OncoRepsonse, about the tumor microenvironment, how his company is studying elite responders to immunotherapies to discover new antibodies to modulate the immune system, and his company’s lead program in clinical development.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Learning from “Elite” Responders to Develop Better Immunotherapies

0:00 28:10

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 28 minutes long.

When was this The Bio Report episode published?

This episode was published on October 27, 2022.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.